Longeveron’s (LGVN) Hold Rating Reaffirmed at Maxim Group

Longeveron (NASDAQ:LGVN)‘s stock had its “hold” rating reissued by analysts at Maxim Group in a research note issued to investors on Monday,Benzinga reports.

A number of other research firms have also weighed in on LGVN. Wall Street Zen lowered shares of Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. HC Wainwright decreased their target price on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.50.

Longeveron Price Performance

LGVN traded up $0.00 during trading on Monday, reaching $0.85. The company’s stock had a trading volume of 475,661 shares, compared to its average volume of 3,969,999. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $0.91 and a two-hundred day simple moving average of $0.73. Longeveron has a 1 year low of $0.48 and a 1 year high of $1.80. The company has a market cap of $19.69 million, a price-to-earnings ratio of -0.66 and a beta of -0.31.

Longeveron (NASDAQ:LGVN) last released its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.20. Longeveron had a negative net margin of 1,893.58% and a negative return on equity of 199.79%. The business had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.11 million. As a group, analysts anticipate that Longeveron will post -0.7 EPS for the current year.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.